Some paper shredders may have inadequate shielding around the blade area thus causing children and even pets to potentially be injured by the blades when the shredder is activated, often while the shredder is in “auto on” mode and activated by the placement of anything in the paper input area.  The shielding is sometimes flimsy and may expand thus allowing the entry of larger objects such as fingers.  Hair can also become caught in shredders, leading to scalp injury.  The paper shredder should be unplugged at all times except when in use in order to help prevent children, pets, and others being involved in paper shredder accidents involving the “auto on” feature.

The Consumer Safety Commission issued an extensive report in December 2004 informing manufacturers of these types of safety issues.  Manufacturers may not have recalled defective products or taken other needed corrective actions.

If you or a loved one have been injured by a paper shredder, please contact us today for a free potential claim evaluation.

The Need to Act Quickly

If you or a loved one has been injured by a paper shredder, you should contact us immediately. You may be entitled to compensation for your injuries or loss and we can help. If you delay, you may forever lose rights and compensation!  Statutes of Limitations vary by state and are complex.  Failure to act quickly may cause you to lose your potential claim if the statute of limitations period passes.

We have a team of product defect lawyers standing by and ready to assist you with your case, and all cases are taken on a contingency fee basis, which means you do not pay for our services unless you receive an award or settlement.

Please fill out a form on this website, or call our office so that we can get started on evaluating your potential case right away.

Over $600 Million Recovered

Since it’s founding in 1995, The Mulligan Law Firm has recovered over 600 million dollars for our clients in settlements for injuries. Our experienced team of product liability lawyers stands ready to represent you and help you receive any compensation you deserve.

For more information on The Mulligan Law Firm including our terms and conditions of use of this site, please visit our home page at www.mulliganlaw.com.

Please note that you are not considered a client until you have signed a retainer agreement and your case has been accepted by us.

The advisers voted 21-5 that the information labels for the class of pills should be changed to more clearly reflect the potential for blood clots as a side effect of the medications.

The FDA does not have to follow the panels’ advice.

The clarity of the language and the way the label communicates the information formed part of the discussion about how the label should be updated to warn women who take the class of birth control medications.

Drospirenone is similar to the naturally occurring female hormone progesterone.

The FDA acknowledges that the newest generation birth control pills may raise the risks of blood clots.

Yas and Yasmin and similar medications combine drospirenone, a synthetic versions of the female hormone progesterone, with estradiol, a form of the female hormone estrogen.

Bayer faces thousands of lawsuits over injuries allegedly caused by the medications.

Lawyers have cited FDA reports on at least fifty deaths of those taking the medications between 2004 and 2008.

Some womens’ health advocates are so concerned by Yaz and Yasmin that they believe the medications should be taken off the market since there are safer options available.

If you or somebody you know took an antidepressant while pregnant and your child was born with an omphalocele, you should contact our lawyers immediately.

We are actively seeking birth defects claims like these in order to represent the legal interests of children and families affected by the manufacturer’s failure to warn mothers of the potential for congenital birth defects as a result of taking their products.

What is Omphalocele?

An omphalocele is a congenital hernia in which the infant’s intestine and/or other abdominal organs protrude out of the navel.

Omphaloceles occur when the abdominal wall does not close properly during fetal development.

The extent and seriousness to which abdominal organs protrude through the base of the umbilical cord will vary with each individual case.

What SSRI Antidepressants Are Possibly Linked to Omphalocele?

The following antidepressants are the primary drugs potentially linked to the development of omphalocele in newborn infants and babies if their mothers took these drugs during pregnancy:

•Zoloft (Sertraline)
•Paxil (Paroxetine)
•Lexapro (Escitalopram)
•Celexa (Citalopram)
•Prozac (Fluoxetine)
•Symbyax (fluoxetine and olanzapine)
•Wellbutrin (Bupropion)
•Effexor (Venlafaxine)
•Generics and other types of this class of drugs (SSRI).

If you or a loved one have suffered an injury after taking any of these or other similar drugs, or their generics, please contact us immediately for a free potential claim evaluation.  Failure to act quickly may cause you to lose your potential legal rights if the statute of limitations period passes.

Please fill out any of the contact forms on this website or call us today so that we can mail you a free questionnaire.

The ASR hip cup is a metal-on-metal ball and socket, large diameter hip resurfacing device.

DePuy, the company that manufactures the ASR hip cup (pronounced dee-pew), was acquired by Johnson & Johnson in 1998.

The cause of the DePuy ASR / ASRXL Cup hip implant problem / failure issue is under investigation.

Metal debris early in the placement of this implant may cause inflammation, leading to damaged muscles and soft tissue.

The result?  An expensive and painful surgery intended to last at least a decade often requires revision within two to three years.

If you or a loved one has been adversely affected / injured after surgical implantation of a DePuy Acetabular Cup, please contact us immediately for a free consultation.

Please contact the attorneys of The Mulligan Law Firm at 866-529-0001 if you would like to discuss a qui tam whistleblower action.

Company;  Total Penalty;  Violation(s);  Year;  Major Drug Products Involved;  Laws Allegedly Violated (if applicable)
 

• GlaxoSmithKline; $3.4 billion; Financial Violation; 2006.
• Pfizer; $2.3 billion; Unlawful Promotion / Kickbacks; 2009; Bextra / Geodon / Zyvox / Lyrica; False Claims Act / Food, Drug, and Cosmetics Act.
• Eli Lilly; $1.4 billion; Unlawful Promotion; 2009; Zyprexa; False Claims Act / Food, Drug, and Cosmetics Act. 
• TAP Pharmaceutical Products; $875 million; Overcharging Govt Health Programs / Kickbacks; 2001; Lupron; False Claims Act / Prescription Drug Marketing Act.   
• GlaxoSmithKline; $750 million; Poor Manufacturing Practices; 2010; Kytril / Bactroban / Paxil CR / Avandamet; False Claims Act / Food, Drug, and Cosmetics Act.
• Serono; $704 million; Unlawful Promotion / Kickbacks / Monopoly Practices; 2005; Serostim; False Claims Act.     
• Merck; $650 million; Overcharging Govt Health Programs / Kickbacks; 2008; Zocor / Vioxx / Pepcid; False Claims Act / Medicaid Rebate Statute.     
• Purdue; $601 million; Unlawful Promotion; 2007; Oxycontin; False Claims Act.   
• Allergan; $600 million; Unlawful Promotion; 2010; Botox; False Claims Act / Food, Drug, and Cosmetics Act.    
• AstraZeneca; $520 million; Unlawful Promotion / Kickbacks; 2010; Seroquel; False Claims Act.    
• Bristol‐MyersSquibb; $515 million; Unlawful Promotion / Kickbacks / Overcharging Govt Health Programs; 2007; Abilify / Serzone; False Claims Act / Food, Drug, and Cosmetics Act.    
• Schering‐Plough; $500 million; Poor Manufacturing Practices; 2002; Claritin; FDA Current Good Manufacturing Practices.    
• Schering‐Plough; $435 million; Unlawful Promotion / Kickbacks / Overcharging Govt Health Programs; 2006; Temodar / Intron A / K‐Dur / Claritin RediTabs; False Claims Act / Food, Drug, and Cosmetics Act.    
• Pfizer; $430 million; Unlawful Promotion; 2004; Neurontin; False Claims Act / Food,Drug, and Cosmetics Act.      
• Cephalon; $425 million; Unlawful Promotion; 2008; Actiq / Gabatril / Provigil; False Claims Act / Food, Drug, and Cosmetics Act.    
• Novartis; $423 million; Unlawful Promotion / Kickbacks; 2010; Trileptal; False Claims Act / Food, Drug, and Cosmetics Act.    
• AstraZeneca; $355 million; Overcharging Govt Health Programs; 2003; Zoladex; Prescription Drug Marketing Act.    
• Schering‐Plough; $345 million; Overcharging Govt Health Programs / Kickbacks; 2004; Claritin; False Claims Act / Anti‐Kickback Statute.    
• Forest Laboratories; $313 million; Unlawful Promotion / Concealing Study Findings / Kickbacks / Illegal Distribution; 2010; Levothyroid /Celexa / Lexapro; False Claims Act / Food, Drugs, and Cosmetics Act.    
• Johnson & Johnson (State settlement); $258 million; Unlawful Promotion; 2010; Risperdal; Medical Assistance Program Integrity Law.

This list of Top 20 Largest Pharmaceutical Company Settlements is located in:  Sammy Almashat, M.D., M.P.H.,  Charles Preston, M.D., M.P.H., Timothy Waterman, B.S., Sidney Wolfe, M.D., Rapidly Increasing Criminal and Civil Monetary Penalties Against the Pharmaceutical Industry:  1991 – 2010, Public Citizen’s Health Research Group, December 16, 2010.

If you or a loved one have a whistleblower claim we would like to speak with you.   The Mulligan Law Firm is particularly interested in speaking to individuals with claims in Texas, Pennsylvania, California and Florida, but please call regardless of where you live in the United States or elsewhere if you believe you have a Qui Tam Whistleblower action to discuss with our attorneys. 

Any delay may cause you to lose your potential legal rights permanently.

• Pharmaceutical Companies or sales representatives paying kickbacks and inducements to doctors / physicians, pharmacists, and/or hospitals to prescribe or in any manner favor their drugs.
• Off-label marketing of drugs / medications.
• Selling, manufacturing, or distributing adulterated pharmaceutical drugs;  i.e. where the required standards of safety, quality, correct strength, and/or purity of drugs have not been met. 
• Kickbacks or any other fraudulent activity by pharmaceutical companies.
• Providing false data to the FDA or withholding negative information / data from the Food and Drug Administration (FDA) concerning the efficacy of a drug and/or medical device during clinical research trials to get FDA approval to sell / market the medication, drug, or device. 
• Manufacturing, diverting, selling, etc., tainted or substandard drugs.
• Misrepresentation of the “federal ceiling price” or “best price” or other benchmark prices that pharmaceutical companies report to the Medicaid and Medicare programs.
• Overcharging on “340B” program drugs.
• Excessive markup on external vendor services and products resold to the government.
• Excessive and unnecessary products and services on goods / contracts sold to the government.
• Delivery of poor quality goods or services to the government.
• Non-conformance to government contract specifications.
• Fraudulently billing the government for work not performed.
• Overvaluing leases or rents that the government must pay.
• Passing incomplete work off as complete.
• Improper billing practices.
• Over pricing of any kind.
• Inappropriate travel grants.
• Wasteful University Studies.
• University Grant Fraud.
• Accounting not in compliance with GAAP.
• Deliberate delivery delay for government contracted services.
• Deliberate production delay for government contracted services
• False or overstated “padded” legal billing for government entities by major law firms.
• Non-conformance with federal wage and employment laws.
• Quality Control Failures on Government Contracted Services
• Double billing.
• Final billing on unfinished contracts.

Please fill out a form on this website or call us immediately at the number on our home page if you have information about any of the above.

A surgeon and consultant to Zimmer Holdings called for a Zimmer NexGen® knee recall to be issued. The reason this action was taken was as result of repeated observation of problems, later to be followed by a study confirming the initial findings.

The model at issue, the NexGen® CR-Flex, is designed to provide a greater range of motion than the standard NexGen.

The most commonly used method of implanting an artificial knee is by using an adhesive to bond the thigh bone to the portion of the device that bends, cementing the two together. Some specialists avoid adhesives because cement can break down, causing failure of the device. Because of this, Zimmer sells an uncemented version of the CR-Flex that relies on the bone naturally growing into the implant. This uncemented version is the source of the problems and complaints.

“…he gave the device, which is supposed to last about 15 years, to about 125 patients in 2005, the first full year he used it. But by early 2006, some X-rays showed lines where the implant met the thigh bone, an indication that the device was loose and had not fused completely. Patients could walk, but they were reporting pain, apparently a result of the loose joint.”  – New York Times article titled “Surgeon vs. Knee Maker:  Who’s Rejecting Whom?” 18 June 2010

Several prominent surgeons, one the former consultant for Zimmer mentioned above, first presented their study at a medical meeting in the fall of 2009 and again this year at a national meeting of the American Association of Orthopedic Surgeons.

The uncemented Zimmer knee was found to fail in 9 percent of 100 patients featured in the study. Furthermore, the knee was observed to be loose in approximately 50% of the patients, requiring additional surgeries in some of the patients.

The Zimmer NexGen® CR-Flex Porous Femoral components are replacement knee products that have been associated with a high number of reports of:

•Loosening of Replacement Knees (50% in study mentioned above)
•Knee replacement failure
•Surgery required to correct complications
•Other knee complications and pain
If you or a loved one has been seriously injured after surgical implantation with any of the Zimmer NexGen® CR femoral components, please contact us immediately for a free consultation.

These problems could include:

•Unexplained pain following knee replacement
•Loosening of replacement knee
•Revision knee surgery to correct problems 

Who We Are
The Mulligan Law Firm, a national law firm located in Dallas, Texas, provides legal information and resources for injured individuals and their families. The firm has successfully resolved over $600,000,000 in claims for its clients. Formed in 1995, it has been helping people for almost 15 years, with the strength and experience to represent plaintiffs in all 50 states.

The Mulligan Law Firm is currently investigating injury claims involving Zimmer NexGen® Knee Replacements. 

If you or a loved one has been seriously injured after surgical implantation of a Zimmer NexGen® Knee Replacement, it is important that you consult with a legal professional immediately. The Mulligan Law Firm has experienced lawyers standing by to help you.

You may be entitled to compensation for your injuries. We take all cases on a contingency-fee basis, which means you do not pay for our services unless you receive an award or compensation.

Do not delay, as your rights and compensation may be lost forever if you wait.  Call us now at 866 529 0001, Extension 245, or simply fill a form out on this website.

On November 19, 2010 the FDA asked manufacturers of propoxyphene (Darvon®, Darvocet®) for a product recall. 

Propoxyphene is an opioid used to treat mild to moderate pain.  Approved by the FDA and available since 1957, propoxyphene is manufactured by Xanodyne Pharmaceuticals Inc., which markets the drug as Darvon® and Darvocet®. The difference between the two painkillers is that while Darvon® is composed entirely of propoxyphene, Darvocet® combines propoxyphene and acetaminophen.

Some of the other limitations of propoxyphene-containing medicines include:
·         As weak painkillers, they provide minimal benefits.
·         The combination of propoxyphene and acetaminophen (Darvocet®) is no more effective than acetaminophen on its own.
·         The difference between the dose needed for treatment and a harmful dose is too small, increasing the potential for overdose.
·         As an opioid, it is also addictive.

“The FDA is advising health care professionals to stop prescribing propoxyphene to their patients, and patients who are currently taking the drug should contact their health care professional as soon as possible to discuss switching to another pain management therapy.” – FDA News Release, November 19, 2010.

Severe and even fatal responses to Darvon® and other pain medications containing propoxyphene have been reported, such as:
Death
Heart Attack
Heart Arrhythmia
Suicide
Overdose

If you or a loved one have experienced any side effects such as these from taking these medications, please contact us as soon as possible for a free potential claim evaluation.  Please fill a form out on this website or call our toll free number for additional information.   Always consult carefully with your doctor prior to stopping any medication.

Severe and even fatal responses to Januvia® and Janumet® have been reported, such as:

•Death, Acute Pancreatitis, Necrotizing Pancreatitis, Hemorrhagic Pancreatitis

and

•Cutaneous Vasculitis

If you or a loved one have been prescribed Januvia or Janumet and have experienced any of these side-effects, please contact us immediately for a free consultation.

Always see your physician before you stop taking any medications, including Januvia® or Janumet®. 

If you have taken Januvia and have questions, please do not hesitate to contact us immediately.